公开(公告)号：WO2015047982A3

公开(公告)日：2015-11-19

申请号：PCT/US2014056898

申请日：2014-09-23

Applicant: CHDI FOUNDATION INC

Inventor： DOMINGUEZ CELIA ,  TOLEDO-SHERMAN LETICIA M ,  PRIME MICHAEL ,  MITCHELL WILLIAM ,  WENT NAOMI

IPC: A61K31/381

CPC classification number: C07D413/12 ,  C07D209/08 ,  C07D213/46 ,  C07D215/18 ,  C07D217/02 ,  C07D231/56 ,  C07D235/08 ,  C07D237/28 ,  C07D239/74 ,  C07D241/42 ,  C07D261/20 ,  C07D263/56 ,  C07D277/24 ,  C07D277/64 ,  C07D307/79 ,  C07D319/18 ,  C07D333/06 ,  C07D333/10 ,  C07D333/28 ,  C07D407/12

Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease.

Abstract translation: 本文提供了某些化合物或其药学上可接受的盐或前药。 还提供了药物组合物，其包含至少一种本文所述的化合物或其药学上可接受的盐或前药和一种或多种药学上可接受的载体。 描述了治疗患有对抑制KMO活性有响应的某些疾病和病症的患者的方法，其包括向所述患者施用有效减少体征或症状的量的本文所述的至少一种化合物或其药学上可接受的盐或前药 披露了该疾病或病症。 这些疾病包括神经退行性疾病，如亨廷顿病。

公开(公告)号：WO2015187542A8

公开(公告)日：2016-12-29

申请号：PCT/US2015033511

申请日：2015-06-01

Applicant: CHDI FOUNDATION INC

Inventor： DOMINGUEZ CELIA ,  MUÑOZ-SANJUAN IGNACIO ,  LUCKHURST CHRISTOPHER A ,  ALLEN DANIEL R ,  RAPHY GILLES ,  BÛRLI ROLAND W ,  BRECCIA PERLA ,  HAUGHAN ALAN F ,  WISHART GRANT ,  HUGHES SAMANTHA J ,  JARVIS REBECCA E ,  VATER HUW D ,  PENROSE STEPHEN D ,  WALL MICHAEL ,  STOTT ANDREW J ,  SAVILLE-STONES ELIZABETH

IPC: A61K31/423 ,  A61K31/4245 ,  A61K31/4709 ,  C07D413/02 ,  C07D417/02

CPC classification number: C07D417/04 ,  C07C259/08 ,  C07D231/54 ,  C07D231/56 ,  C07D239/70 ,  C07D239/74 ,  C07D239/88 ,  C07D275/04 ,  C07D277/60 ,  C07D401/04 ,  C07D403/04

Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. The condition or disorder mediated by HDAC comprises a neurodegenerative pathology. Accordingly, also provided is a method of treating a neurodegenerative pathology mediated by HDAC in a subject in need of such a treatment, comprising administering to the subject a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt thereof, described herein.

Abstract translation: 提供了式I的某些组蛋白脱乙酰酶（HDAC）抑制剂或其药学上可接受的盐，其组合物及其使用方法。 由HDAC介导的病症或障碍包括神经变性病理学。 因此，还提供了在需要这种治疗的受试者中治疗由HDAC介导的神经变性病理学的方法，其包括向受试者施用治疗有效量的本文所述的至少一种化合物或其药学上可接受的盐。

公开(公告)号：WO2014014900A8

公开(公告)日：2014-03-27

申请号：PCT/US2013050664

申请日：2013-07-16

Applicant: CHDI FOUNDATION INC ,  DOMINGUEZ CELIA ,  LUCKHURST CHRISTOPHER A ,  BURLI ROLAND W ,  STOTT ANDREW J ,  BRECCIA PERLA

Inventor： DOMINGUEZ CELIA ,  LUCKHURST CHRISTOPHER A ,  BURLI ROLAND W ,  STOTT ANDREW J ,  BRECCIA PERLA

IPC: A01N37/08 ,  A61K31/15 ,  A61K31/19

CPC classification number: A61K31/505 ,  A61K31/165 ,  A61K31/357 ,  A61K31/421 ,  A61K31/426 ,  A61K31/4418 ,  C07B2200/07 ,  C07C259/08 ,  C07C2601/02 ,  C07D213/56 ,  C07D213/61 ,  C07D213/74 ,  C07D215/18 ,  C07D237/08 ,  C07D239/26 ,  C07D239/30 ,  C07D239/34 ,  C07D241/12 ,  C07D263/32 ,  C07D263/56 ,  C07D277/30 ,  C07D277/64 ,  C07D295/155 ,  C07D311/58 ,  C07D319/18 ,  C07D401/04 ,  C07D417/04

Abstract: Provided are certain histone deacetylase (HDAC) inhibitors, compositions thereof, and methods of their use.

Abstract translation: 提供了某些组蛋白脱乙酰酶（HDAC）抑制剂，其组合物及其使用方法。